Clinical Trials Logo

Portal Vein Tumor Thrombus clinical trials

View clinical trials related to Portal Vein Tumor Thrombus.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06040177 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Start date: February 2, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of SBRT combined with cardonilizumab and lenvastinib in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus

NCT ID: NCT03178656 Recruiting - Clinical trials for Portal Vein Tumor Thrombus

A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis

Start date: December 15, 2016
Phase: Phase 4
Study type: Interventional

According to the guidelines recommended, only a few new targeted therapy drugs treatment, such as Sorafenib, is proper. It's 3 year survival rate is only 8% or so. According to our previous study, patients with hepatic carcinoma without portal vein tumor thrombus backbone and the contralateral tumor thrombus applyed tumor excision, along with tumor thrombus, the 3 year survival rate can reach 39.9%, the 5-year survival rate can reach 22.7%, curative effect is obviously better.

NCT ID: NCT02971345 Recruiting - Clinical trials for Hepatocellular Carcinoma

Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus

Start date: January 2017
Phase: Phase 3
Study type: Interventional

It is a prospective and multi-center clinical research in China to compare the efficacy, safety and related impact factors between TACE alone and endovascular brachytherapy combined with stent placement and TACE for HCC with main portal vein tumor thrombus.